



## Cartesian Therapeutics to Participate in Upcoming Investor Conferences

August 26, 2024

GAITHERSBURG, Md., Aug. 26, 2024 (GLOBE NEWSWIRE) – Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in September:

- A fireside chat at the H.C. Wainwright 26<sup>th</sup> Annual Global Investment Conference at 2:30 p.m. ET on Monday, September 9, 2024 in New York, NY
- A fireside chat at the Cantor Global Healthcare Conference at 9:45 a.m. ET on Tuesday, September 17, 2024 in New York, NY

A live webcast of the fireside chats are expected to be accessible in the Events section of the Company’s website at [www.cartesiantherapeutics.com](http://www.cartesiantherapeutics.com), where an archived replay of the events will also be available for a limited time.

### About Cartesian Therapeutics

Cartesian Therapeutics is a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a potential first-in-class mRNA CAR-T in Phase 2b clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T. For more information, please visit [www.cartesiantherapeutics.com](http://www.cartesiantherapeutics.com) or follow the Company on [LinkedIn](#) or [X](#), formerly known as Twitter.

### Contact Information:

Investor Relations:

Argot Partners

[cartesian@argotpartners.com](mailto:cartesian@argotpartners.com)

Media:

David Rosen

Argot Partners

[david.rosen@argotpartners.com](mailto:david.rosen@argotpartners.com)



Source: Cartesian Therapeutics, Inc.